JF
James E Flynn
Director10% Owner
James E FlynnDirector10% Owner
James E Flynn insider trades: Larimar Therapeutics (LRMR) stock buys and sales
Director, Larimar Therapeutics Last trade Feb 27, 2026 328 Form 4 filings
$70.9M
Sold, last 12 months
2 sales
$25.0M
Bought, last 12 months
4 buys
504
Open-market trades
since 2006
95
Companies
last trade 2026
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
PBLSParabilis Medicines
10% Owner · last filing Jun 11, 2026
No market trades
LRMRLarimar Therapeutics
Director · last filing May 20, 2026
+$133.5M
NUVLNuvalent
Director · last filing Jul 17, 2026
-$266.4M
+$21.8M
SPRYARS Pharmaceuticals
10% Owner · last filing Jul 1, 2025
-$23.8M
PHGEBiomX
Director · last filing Apr 23, 2025
No market trades
BCAXBicara Therapeutics
10% Owner · last filing Sep 17, 2024
+$1.3M
and 89 more companies
Open-market buys and sales
504 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | LRMR | ↑ Buy | 2,000,000 | $5.00 | $10.0M | Through Deerfield Partners, L.P. | Mar 2, 2026 (3d) |
| Feb 27, 2026 | LRMR | ↑ Buy | 1,084,012 | $5.00 | $5.4M | Through Deerfield Private Design Fund IV | Mar 2, 2026 (3d) |
| Feb 27, 2026 | LRMR | ↑ Buy | 1,084,010 | $5.00 | $5.4M | Through Deerfield Private Design Fund II | Mar 2, 2026 (3d) |
| Feb 27, 2026 | LRMR | ↑ Buy | 831,978 | $5.00 | $4.2M | Through Deerfield Healthcare Innovations | Mar 2, 2026 (3d) |
| Nov 24, 2025 | NUVL | ↓ Sell | 371,287 | $95.44 | $35.4M | Through Deerfield Healthcare Innovations | Nov 24, 2025 (0d) |
| Nov 24, 2025 | NUVL | ↓ Sell | 371,287 | $95.44 | $35.4M | Through Deerfield Private Design Fund IV | Nov 24, 2025 (0d) |
| Jul 31, 2025 | LRMR | ↑ Buy | 3,387,539 | $3.20 | $10.8M | Through Deerfield Private Design Fund IV | Aug 4, 2025 (4d) |
| Jul 31, 2025 | LRMR | ↑ Buy | 3,387,529 | $3.20 | $10.8M | Through Deerfield Private Design Fund II | Aug 4, 2025 (4d) |
| Jul 31, 2025 | LRMR | ↑ Buy | 2,599,932 | $3.20 | $8.3M | Through Deerfield Healthcare Innovations | Aug 4, 2025 (4d) |
| Jun 27, 2025 | SPRY | ↓ Sell | 370,075 | $18.46 | $6.8M | Through Deerfield Private Design Fund II | Jul 1, 2025 (4d) |
| Jun 27, 2025 | SPRY | ↓ Sell | 370,074 | $18.46 | $6.8M | Through Deerfield Private Design Fund IV | Jul 1, 2025 (4d) |
| Nov 12, 2024 | SPRY | ↓ Sell | 281,635 | $18.01 | $5.1M | Through Deerfield Private Design Fund II | Nov 13, 2024 (1d) |
| Nov 12, 2024 | SPRY | ↓ Sell | 281,635 | $18.01 | $5.1M | Through Deerfield Private Design Fund IV | Nov 13, 2024 (1d) |
| Oct 22, 2024 | NUVL | ↓ Sell | 1,000,000 | $97.75 | $97.8M | Through Deerfield Healthcare Innovations | Oct 24, 2024 (2d) |
| Oct 22, 2024 | NUVL | ↓ Sell | 1,000,000 | $97.75 | $97.8M | Through Deerfield Private Design Fund IV | Oct 24, 2024 (2d) |
| Sep 17, 2024 | BCAX | ↑ Buy | 35,000 | $18.00 | $630K | Through Deerfield Private Design Fund V, | Sep 17, 2024 (0d) |
| Sep 17, 2024 | BCAX | ↑ Buy | 35,000 | $18.00 | $630K | Through Deerfield Partners, L.P. | Sep 17, 2024 (0d) |
| Mar 12, 2024 | AHCO | ↓ Sell | 350,000 | $10.90 | $3.8M | Through Deerfield Partners, L.P. | Mar 12, 2024 (0d) |
| Feb 16, 2024 | LRMR | ↑ Buy | 1,430,206 | $8.74 | $12.5M | Through Deerfield Private Design Fund IV | Feb 16, 2024 (0d) |
| Feb 16, 2024 | LRMR | ↑ Buy | 1,430,206 | $8.74 | $12.5M | Through Deerfield Private Design Fund II | Feb 16, 2024 (0d) |
| Feb 16, 2024 | LRMR | ↑ Buy | 1,430,205 | $8.74 | $12.5M | Through Deerfield Partners, L.P. | Feb 16, 2024 (0d) |
| Dec 30, 2022 | ONCR | ↓ Sell | 149,691 | $0.26 | $39K | Through Deerfield Private Design Fund II | Dec 30, 2022 (0d) |
| Dec 30, 2022 | ONCR | ↓ Sell | 149,690 | $0.26 | $39K | Through Deerfield Healthcare Innovations | Dec 30, 2022 (0d) |
| Dec 30, 2022 | ONCR | ↓ Sell | 36,854 | $0.26 | $10K | Through Deerfield Partners, L.P. | Dec 30, 2022 (0d) |
| Dec 27, 2022 | ONCR | ↓ Sell | 32,670 | $0.27 | $9K | Through Deerfield Private Design Fund II | Dec 27, 2022 (0d) |
| Dec 27, 2022 | ONCR | ↓ Sell | 32,669 | $0.27 | $9K | Through Deerfield Healthcare Innovations | Dec 27, 2022 (0d) |
| Dec 27, 2022 | ONCR | ↓ Sell | 8,045 | $0.27 | $2K | Through Deerfield Partners, L.P. | Dec 27, 2022 (0d) |
| Dec 21, 2022 | ONCR | ↓ Sell | 57,100 | $0.29 | $17K | Through Deerfield Healthcare Innovations | Dec 21, 2022 (0d) |
| Dec 21, 2022 | ONCR | ↓ Sell | 57,099 | $0.29 | $17K | Through Deerfield Private Design Fund II | Dec 21, 2022 (0d) |
| Dec 21, 2022 | ONCR | ↓ Sell | 14,059 | $0.29 | $4K | Through Deerfield Partners, L.P. | Dec 21, 2022 (0d) |
| Dec 15, 2022 | ONCR | ↓ Sell | 6,137 | $0.39 | $2K | Through Deerfield Healthcare Innovations | Dec 15, 2022 (0d) |
| Dec 15, 2022 | ONCR | ↓ Sell | 6,137 | $0.39 | $2K | Through Deerfield Private Design Fund II | Dec 15, 2022 (0d) |
| Dec 15, 2022 | ONCR | ↓ Sell | 1,512 | $0.39 | $585 | Through Deerfield Partners, L.P. | Dec 15, 2022 (0d) |
| Nov 3, 2022 | NUVL | ↑ Buy | 650,000 | $33.50 | $21.8M | Through Deerfield Partners, L.P. | Nov 7, 2022 (4d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Private Design Fund II | Sep 20, 2022 (4d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Healthcare Innovations | Sep 20, 2022 (4d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Private Design Fund IV | Sep 20, 2022 (4d) |
| Sep 16, 2022 | LRMR | ↑ Buy | 2,777,777 | $3.15 | $8.7M | Through Deerfield Partners, L.P. | Sep 20, 2022 (4d) |
| Jun 6, 2022 | MIRM | ↓ Sell | 20,212 | $25.01 | $505K | Through Deerfield Private Design Fund IV | Jun 8, 2022 (2d) |
| Jun 6, 2022 | MIRM | ↓ Sell | 18,266 | $25.01 | $457K | Through Deerfield Healthcare Innovations | Jun 8, 2022 (2d) |
| May 10, 2022 | PEPG | ↑ Buy | 208,333 | $12.00 | $2.5M | Through Deerfield Partners, L.P. | May 10, 2022 (0d) |
| May 10, 2022 | PEPG | ↑ Buy | 208,333 | $12.00 | $2.5M | Through Deerfield Private Design Fund V, | May 10, 2022 (0d) |
| Oct 26, 2021 | XLO | ↑ Buy | 387,500 | $16.00 | $6.2M | Through Deerfield Private Design Fund V, | Oct 28, 2021 (2d) |
| Oct 26, 2021 | XLO | ↑ Buy | 387,500 | $16.00 | $6.2M | Through Deerfield Partners, L.P. | Oct 28, 2021 (2d) |
| Jul 30, 2021 | DALS | ↑ Buy | 1,600,000 | $10.00 | $16.0M | Through Deerfield Partners, L.P. | Aug 3, 2021 (4d) |
| Jul 19, 2021 | AFIB | ↑ Buy | 680,592 | $14.00 | $9.5M | Through Deerfield Private Design Fund II | Jul 21, 2021 (2d) |
| Jul 19, 2021 | AFIB | ↑ Buy | 390,836 | $14.00 | $5.5M | Through Deerfield Partners, L.P. | Jul 21, 2021 (2d) |
| Jul 9, 2021 | MIRM | ↓ Sell | 99,325 | $15.81 | $1.6M | Through Deerfield Special Situations Fun | Jul 13, 2021 (4d) |
| Jul 7, 2021 | MIRM | ↓ Sell | 66,675 | $16.29 | $1.1M | Through Deerfield Special Situations Fun | Jul 7, 2021 (0d) |
| Jun 30, 2021 | LRMR | ↑ Buy | 228,571 | $8.75 | $2.0M | Through Deerfield Private Design Fund IV | Jul 2, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LRMR insiders
Open-market trades in the last 12 months
Thomas Edward Hamilton
Insider
2 buys
Jul 6, 2026
Deerfield Mgmt L.P.
Director
1 buy
Feb 27, 2026
Jeffrey W Sherman
Insider
1 buy
Feb 27, 2026
Frank E Thomas
Insider
1 buy
Feb 27, 2026
Deerfield Partners, L.P.
Director
1 buy
Feb 27, 2026
Deerfield Private Design Fund III, L.P.
Director
1 buy
Feb 27, 2026
Deerfield Management Company, L.P.
Director
1 buy
Feb 27, 2026
Deerfield Healthcare Innovations Fund, L.P.
Director
1 buy
Feb 27, 2026
About James E Flynn's insider trades
James E Flynn is a director at Larimar Therapeutics (LRMR). Since Feb 6, 2006, James has reported 255 open-market purchases worth $883.0M and 249 sales worth $543.4M on SEC Form 4. In the last 12 months: 4 buys ($25.0M) and 2 sales ($70.9M).
Their filings also include conversions (51 filings), grants and awards (40 filings), other transactions (30 filings), option exercises (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LRMR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.